TPO and autoimmune thrombocytopenic purpura: The characteristics making avatrombopag a potentially beneficial option in the treatment of ITP compared with other TPO-RAs are the low potential for side effects, the absence of hepatotoxicity, the convenient oral route of administration, and the lack of interactions with food and other medications [22,23].